A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.
Tag: Kidney Cancer
The Cancer Research Institute and the Kidney Cancer Association Announce a Collaboration to Co-Fund Kidney Cancer Immunotherapy Research
The Cancer Research Institute and the Kidney Cancer Association are collaborating on a new kidney cancer immunotherapy research grant.
Widespread disparities exist in treating advanced cancers
A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.
Children’s Research Institute at UT Southwestern scientists discover kidney cancers rely on mitochondrial metabolism to metastasize
Contrary to how tumors operate while still in the kidney, metastatic kidney cancers rely heavily on mitochondrial metabolism, according to new research from Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Nature.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Cancer researchers receive grant to combat aggressive kidney cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) have received an $800,000 grant from the V Foundation to find new ways to treat and prevent a severe form of kidney cancer associated with a hereditary syndrome caused by mutations in the fumarate hydratase (FH) gene.
Wistar Scientists Develop Novel Antibody Treatment for Kidney Cancer
Wistar scientists have built upon BTE technology to develop new and improved recombinant and synthetic DNA versions of therapeutic antibodies that target CA9, called Persistent Multivalent T Cell Engager (CA9-PMTE), that shows promise in pre-clinical models as a potent, long-lasting treatment against ccRCC.
Drug targeting clear cell renal cell carcinoma shows promising approach
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC). Published in Clinical Cancer Research, the findings illustrate the potential of siRNA for cancer therapy.
AACR: Novel immunotherapies show promise for patients with kidney cancer and for solid organ transplant recipients with skin cancer
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
Kidney cancer treatments and tumor biology can activate different immune-modifying processes in patients
The findings out of Dana-Farber Cancer Institute highlight that the mechanisms of immune modulation are different in patients treated with immunotherapy and anti-angiogenic combinations. The results also point to the role of tumor biology in the diversity and actions of tumor-infiltrating immune cells brought into action by these treatments. The findings might be important for predicting or understanding treatment outcomes in advanced kidney cancer.
Urology on the Beach Meeting Highlights Innovative Approaches to Multidisciplinary Care
Renowned urologists from leading academic centers shared their insights and clinical recommendations at Urology on the Beach, a three-day professional conference hosted by the Desai Sethi Urology Institute (DSUI) at the University of Miami Miller School of Medicine.
Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus
New study finds everolimus benefits high-risk kidney cancer patients
Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
High-dose radiation offers new treatment option for older patients with inoperable kidney tumors
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests.
Global Speakers, Cutting-edge Topics, Surgical Theater on Tap for Desai Sethi Urology Institute’s Urology on the Beach 2024
Desai Sethi Urology Institute at the University of Miami Miller School of Medicine will host its second annual, in-person Urology on the Beach meeting, January 19 to 21, 2024, at the Fontainebleau Hotel in Miami Beach.
New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression.
The study, published today in Nature Cancer, demonstrates that the loss of a cluster of interferon receptor (IFNR) genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability. This genomic feature may be used to help clinicians predict a tumor’s potential to become metastatic and treatment resistant.
Study improves prediction of therapy response in patients with metastatic renal cell carcinoma
Renal cell carcinoma is the most common form of kidney cancer. To treat metastatic renal cancer, combinations of immunotherapies are used as the first line of treatment.
MD Anderson Research Highlights for May 24, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Three-drug combination slows progression of advanced kidney cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research published in The New England Journal of Medicine and led by an oncologist from Dana-Farber Cancer Institute.
Combination therapy a promising option for advanced kidney cancer patients already treated with immunotherapy
In this study led by Dana-Farber Cancer Institute, interim results of the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor, show promising anti-tumor activity in this pre-treated patient group. The results suggest that the combination might fill and unmet need and provides a rationale for further study of combining a VEGF TKI and a HIF-2 inhibitor.
Genes reveal kidney cancer’s risk of recurrence
A decade-long international study into kidney cancer has shown that doctors can predict the likelihood of a patient’s disease returning by looking at DNA mutations in their tumours.
‘Urology on the Beach’ Conference Highlights Advances in Research and Patient Care
From urologic cancers to female urology to male infertility to kidney stones and sexual health, top urologists from throughout the nation shared their insights and practical tips at “Urology on the Beach,” a conference hosted January 13-15 by the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine.
Taming Overactive mTOR in Renal Cell Cancer
In a new study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers.
New Study Shows Sugar-Sweetened Drinks Increase Risk of Cancer Mortality
In a large study led by researchers at the American Cancer Society, men and women who drank two or more servings of sugar-sweetened beverages (SSB) per day, compared to people who never drank, had a five percent increased risk of death from an obesity-related cancer, including gastrointestinal, postmenopausal breast, endometrial and kidney cancer.
Three-drug combination slows progression of advanced kidney cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
Novel Treatment for Rare Form of Kidney Cancer Uncovered
Chromophobe renal cell carcinoma (ChRCC) is a rare form of kidney cancer for which there are currently no proven treatments for metastatic or unresectable disease. In a study led by investigators from Brigham and Women’s Hospital, researchers report the first…
MD Anderson Research Highlights for May 4, 2022
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
New study shows that different types of cancers are likely to spread to specific areas of the brain
Brain metastasis occurs when cancer in one part of the body spreads to the brain. The lifetime incidence of such metastatic brain tumors in cancer patients is between 20%-45%, research shows.
Hackensack University Medical Center’s Department of Urology Presented 12 Abstracts at the American Urological Association 2021 Annual Meeting
Hackensack University Medical Center presented 12 abstracts at the American Urological Association’s (AUA) 2021 Annual Meeting, held virtually, September 10-13, 2021.
Exploring the Impact of Blood Clots in the Veins during Renal Cell Carcinoma Surgery
Research Results from Rutgers Cancer Institute of New Jersey Presented at American Urological Association Annual Meeting
FDA Approval Of Belzutifan Culminates 25-Year Journey at UTSW From Gene Discovery to A First-In-Class Drug
DALLAS – Aug. 23, 2021 – A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.
UT Southwestern Investigators Report First Analysis Of Pioneering Kidney Cancer Radiation Approach in Clinical Trial
A new approach using precisely targeted, high-dose radiation to treat invasive kidney cancer proves safe, based on a clinical trial by the UT Southwestern Harold C. Simmons Comprehensive Cancer Center’s kidney cancer program. The study, published in the International Journal of Radiation Oncology*Biology*Physics, could offer new hope for patients with a historically dismal condition.
New Insights on Sarcomatoid Kidney Cancer: Roswell Park Reports Clear Benefit from Checkpoint Inhibitors
New collaborative research shows that treatment with immune checkpoint inhibitors (ICIs) has led to a significant improvement in survival and response rates among patients with a particularly aggressive type of kidney cancer: advanced sarcomatoid renal cell carcinoma. The study, which was led by a team from Roswell Park Comprehensive Cancer Center and involved contributors from six centers, is detailed in a presentation at the American Society of Clinical Oncology 2021 virtual annual meeting (abstract 4568).
Analysis reveals how kidney cancer develops and responds to treatment
By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells from which different subtypes originate, the pathways involved and how the tumor microenvironment impacts cancer development and response to treatment.
Rutgers Cancer Institute of New Jersey Experts Available for Comment during Men’s Health Month
New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the…
Immunotherapy drug delays recurrence in kidney cancer patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
Biomarker Could Help Identify Difficult-to-Diagnose Kidney Cancer Subtype
High expression levels of the gene TRIM63 can serve as an accurate and sensitive biomarker of a subtype of kidney cancer known as microphthalmia-associated transcription factor family aberration-associated renal cell carcinomas — or MiTF renal cell carcinoma.
It’s important to distinguish MiTF from other subtypes of kidney cancers — clear cell, papillary and chromophobe — because these tumors may not respond well to standard, front-line treatments and may respond better to other approaches.
Sylvester Researchers Reveal New Link Between Obesity, Chemerin and Kidney Cancer
Research published in the AACR journal Cancer Discovery found that a protein named chemerin is present in higher quantities in the blood of obese individuals and plays an essential role in controlling fat metabolism in kidney cancer cells.
Kidney Cancer: 5 Things You Need to Know
Nearly 74,000 people will be diagnosed with kidney cancer in the United States this year according to the American Cancer Society.
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
Immunotherapy – targeted drug combination improves survival in advanced kidney cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Study examines role of biomarkers to evaluate kidney injury in cancer patients undergoing immunotherapy
A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells.
Dana-Farber research supports FDA approval for immunotherapy combination in advanced kidney cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.
Cancer cases are rising in adolescents and young adults
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
Immunotherapy Side Effect Could Be A Positive Sign For Kidney Cancer Patients
DALLAS – Nov. 2, 2020 – An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern’s Kidney Cancer Program (KCP).
Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.
Novel Discovery Challenges a Current Kidney Cancer Paradigm
Newly published research has reversed our understanding of an aspect of kidney tumor growth. Researchers at Huntsman Cancer Institute at the University of Utah discovered that two key proteins have opposite roles than what was previously believed.
Deep Look at Immune Cells in Patients’ Tumors Reveals Insights on Timing for Treatment Combinations
It’s clear that radiation therapy, or radiotherapy, an approach used to treat cancer since the early 20th century, can be an effective companion to newer, immune-stimulating approaches known as immunotherapy. Research from a team from Roswell Park Comprehensive Cancer Center explains how radiation helps boost the immune system’s ability to fight cancer in combination with immune checkpoint inhibitors — and provides new evidence that the timing of these therapies can make a big difference in how effectively they work together.
Biomarker test highly accurate in detecting early kidney cancer
A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute.
The report in Nature Medicine suggests that if validated in larger trials and applied widely, the non-invasive test could find more early kidney cancers when they haven’t spread, thus reducing the mortality of the disease.